Rouleau J L, de Champlain J, Klein M, Bichet D, Moyé L, Packer M, Dagenais G R, Sussex B, Arnold J M, Sestier F
Institut de Cardiologie, Montreal, Quebec, Canada.
J Am Coll Cardiol. 1993 Aug;22(2):390-8. doi: 10.1016/0735-1097(93)90042-y.
This study was conducted to evaluate the degree of neurohumoral activation around the time of hospital discharge after myocardial infarction.
Because pharmacologic interventions that block the effects of neurohumoral activation improve the prognosis after infarction, we hypothesized that widespread neurohumoral activation persists in some patients until at least the time of hospital discharge and that the determinants of activation vary from one system to another.
Five hundred nineteen patients in the Survival and Ventricular Enlargement Study (SAVE) had plasma neurohormones measured before randomization at a mean of 12 days after infarction. All patients had left ventricular dysfunction (left ventricular ejection fraction < or = 40%) but no overt heart failure.
Although all neurohormones except epinephrine were increased compared with values in age-matched control subjects, plasma norepinephrine (301 +/- 193 vs. 222 +/- 87 pg/ml, p < 0.001), renin activity (3.0 +/- 3.7 vs. 1.2 +/- 1.2 ng/ml per h, p < 0.001), arginine vasopressin (1.9 +/- 6.9 vs. 0.7 +/- 0.3 pg/ml, p < 0.001) and atrial natriuretic peptide (75 +/- 75 vs. 21 +/- 9 pg/ml, p < 0.001) values ranged from normal to very high, indicating a wide spectrum of neurohumoral activation. Activation of one system did not correlate with activation of another. The clinical and laboratory variables most closely associated with neurohumoral activation were Killip class, left ventricular ejection fraction, age and use of diuretic drugs. The association between neurohumoral activation and clinical and laboratory variables varied from one neurohormone to another.
Neurohumoral activation occurs in a significant proportion of patients at the time of hospital discharge after infarction. Which neurohormone is activated and which clinical and laboratory variables determine this activation vary from one neurohormone to another.
本研究旨在评估心肌梗死后出院时神经体液激活的程度。
由于阻断神经体液激活作用的药物干预可改善梗死后的预后,我们推测部分患者中广泛的神经体液激活至少持续至出院时,且激活的决定因素因系统而异。
生存与心室扩大研究(SAVE)中的519例患者在梗死平均12天后随机分组前测量了血浆神经激素。所有患者均有左心室功能障碍(左心室射血分数≤40%)但无明显心力衰竭。
尽管与年龄匹配的对照受试者相比,除肾上腺素外的所有神经激素均升高,但血浆去甲肾上腺素(301±193 vs. 222±87 pg/ml,p<0.001)、肾素活性(3.0±3.7 vs. 1.2±1.2 ng/ml per h,p<0.001)、精氨酸血管加压素(1.9±6.9 vs. 0.7±0.3 pg/ml,p<0.001)和心钠素(75±75 vs. 21±9 pg/ml,p<0.001)的值从正常到非常高,表明神经体液激活范围广泛。一个系统的激活与另一个系统的激活不相关。与神经体液激活最密切相关的临床和实验室变量是Killip分级、左心室射血分数、年龄和利尿剂的使用。神经体液激活与临床和实验室变量之间的关联因神经激素而异。
梗死患者出院时相当一部分患者存在神经体液激活。哪种神经激素被激活以及哪些临床和实验室变量决定这种激活因神经激素而异。